US pharmaceutical giant Eli Lilly announced Wednesday that it will build four additional new manufacturing sites in the ...

Zepbound may not be as widely known as its competitors, but the weight-loss drug may soon be more accessible than the rest.

Eli Lilly & Co.’s stock rose 1.6% Wednesday, after the drug company announced plans to expand its U.S. manufacturing sites by ...

Amgen released financial results for the 4th quarter of 2024. Check out why I continue to cover AMGN stock with a 'Buy' ...

Eli Lilly is expanding the supply and cutting the costs of its weight-loss drug Zepbound, broadening access to more patients ...

In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...

Consumer confidence plummets, some Kia owners need a new engine, and Apple users get a free gift from Adobe. Learn more in ...

Discover Eli Lilly's latest offering of discounted high-dose Zepbound vials, now available for $499 for a four-week supply.

The company is doubling plans for capital spending on U.S. factories as President Donald Trump pressures the pharma industry ...

Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional ...

It comes as companies work to build goodwill with Trump, who has emphasized reshoring manufacturing to the U.S. and reducing ...

Over the last few years, as Eli Lilly has revealed a series of manufacturing investments—each one seemingly more lavish than ...